XW-004
- Generic Name
- XW-004
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06335134
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 211
- Registration Number
- NCT05680155
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
Phase 1
Recruiting
- Conditions
- ObesityType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05184322
- Locations
- 🇦🇺
Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane), Herston, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath